Eli Lilly Completes Acquisition of Verve Therapeutics

Eli Lilly and Company has successfully finalized its acquisition of Verve Therapeutics, Inc., a Boston-based clinical-stage company focused on developing genetic medicines for cardiovascular disease. The acquisition marks a significant opportunity to revolutionize the treatment of cardiovascular disease worldwide. Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development, expressed enthusiasm for the acquisition, emphasizing the potential to deliver lifelong cardiovascular risk reduction with a single treatment.

Lilly's commitment to advancing new discoveries in biotechnology, chemistry, and genetic medicine is aimed at addressing critical health challenges, such as diabetes care, obesity, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers. The company is dedicated to making innovative clinical trials accessible and affordable to a diverse global population.

The press release includes cautionary statements regarding forward-looking information, highlighting potential risks and uncertainties associated with the acquisition. For more information about the acquisition, click here.